TRANSARTERIAL RADIOEMBOLIZATION USING YTTRIUM-90 MICROSPHERES IS A THERAPEUTIC OPTION FOR PATIENTS WITH INT…
Award details are derived from public USAspending.gov records. Not a bid recommendation.
Award details
- Award ID
- W81K0025PA252
- Contractor
- BOSTON SCIENTIFIC CORP
- Awarding agency
- Department of Defense
- Sub-agency / office
- Department of the Army
- Award amount
- $552,770
- Period of performance
- Oct 1, 2025 – Sep 30, 2026
- NAICS
- 325412 — Pharmaceutical Preparation Manufacturing
- Place of performance
- JBSA FT SAM HOUSTON, TX, 782344400, USA
- Competition
- NOT COMPETED UNDER SAP · Set-aside: NO SET ASIDE USED. · 1 offers
- Pricing
- FIRM FIXED PRICE
- Financial breakdown
- Current value $552,770 · Obligated $0 · Potential value $552,770 · Latest action obligation $0
Public award description
TRANSARTERIAL RADIOEMBOLIZATION USING YTTRIUM-90 MICROSPHERES IS A THERAPEUTIC OPTION FOR PATIENTS WITH INTERMEDIATE-OR ADVANCED-STAGE HEPATOCELLULAR CARCINOMA, INCLUDING THOSE WITH RECURRENT OR INOPERABLE HEPATOCELLULAR CARCINOMA.
Related intelligence
- Agency: Department of Defense
- PSC 6515 — Medical and Surgical Instruments, Equipment, and Supplies
- Federal market intelligence software
Related Federal Awards
- · SPE8EQ26F0057 — 8512172601!SUMMIT SHOJI LEUKO REAGENTS U · SUMMIT SHOJI INC. · Department of Defense · $2,706
- · SPE2DP26P0913 — 8512158339!APPLICATOR,SILVER N · SZY HOLDINGS, LLC · Department of Defense · $617
- · SPE2DP26P0931 — 8512173168!AMOXICILLIN TABLETS · MR UNLIMITED, LLC · Department of Defense · $76
- · SPE2D926F6593 — 8512177928!AZITHROMYCIN TABLET · CARDINAL HEALTH, INC. · Department of Defense · $47
- · SPE2DP26V0775 — 8512174419!BACITRACIN ZINC AND · MR UNLIMITED, LLC · Department of Defense · $19
- · SPE2D926F6590 — 8512177923!PROMETHAZINE HYDROC · CARDINAL HEALTH, INC. · Department of Defense · $14